Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets...
Eric R. Lutz, PhD, a recipient of the Pancreatic Cancer Action Network-AACR Career Development Award, studies the development of...
Guest Post by Wafik S. El-Deiry, MD, PhD, FACP Fox Chase Cancer Center
Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung...
Today, the American Association for Cancer Research (AACR), in conjunction with its Fellows of the AACR Academy, Rep. André...
In recognition of June as Cancer Immunotherapy Month, organized by our colleagues at the Cancer Research Institute (CRI), the...
Conference co-chair Elaine R. Mardis, PhD, discusses the third conference in the AACR's Precision Medicine Series, “Integrating Clinical Genomics...
AACR membership includes scientists and physicians from across the cancer research enterprise. Whether basic, translational, or clinical researchers, they...
Over 50 percent of all cancer patients will receive radiation therapy during the course of their treatments. This fact...
Guest Post by Carlos S. Moreno, PhD Winship Cancer Institute of Emory University
Over the years, clinical research has become an integral part of the American Association for Cancer Research’s meetings and...